[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fsV8YPvJZAxjJyTnBXqRuRLFGm20APGefd4J6UKjBUN8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":42,"rows":49},"Universidad Nacional de Colombia",[4],38,false,6,11,8018271,2,24,[14,16,18,21,23,25,27,29],{"name":15,"count":11},"COVID",{"name":17,"count":11},"Breast Cancer Female",{"name":19,"count":20},"P. Falciparum Malaria",1,{"name":22,"count":20},"Athletic Performance",{"name":24,"count":20},"Labor Pain",{"name":26,"count":20},"Neonatal Adaptation",{"name":28,"count":20},"Breast Cancer",{"name":30,"count":20},"Triple Negative Breast Cancer",[32,37],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT06223919","Efficacy\u002FEffectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia","2024-08-20","LC16m8",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06195618","Personalized Vaccine for TNBC Immunotherapy","2027-06-01","Peptide (neoantigen) pulsed autologous Dendritic cell",[43,44,45,46,47,48],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[50,74,96,122,148,166,191,217,245,263,281,306,334,352,373,398,423,450],{"intervention":36,"totalTrials":20,"cells":51},{"EARLY_PHASE1":52,"PHASE1":55,"PHASE2":57,"PHASE3":59,"PHASE4":70,"NA":72},{"trials":53,"activeCount":54},[],0,{"trials":56,"activeCount":54},[],{"trials":58,"activeCount":54},[],{"trials":60,"activeCount":20,"soonestReadout":35},[61],{"nctId":33,"briefTitle":34,"status":62,"phases":63,"primaryCompletion":35,"completion":64,"start":65,"enrollment":66,"conditions":67,"interventions":69},"ACTIVE_NOT_RECRUITING",[46],"2025-12","2023-12-16",8686,[68],"Monkeypox",[36],{"trials":71,"activeCount":54},[],{"trials":73,"activeCount":54},[],{"intervention":41,"totalTrials":20,"cells":75},{"EARLY_PHASE1":76,"PHASE1":78,"PHASE2":88,"PHASE3":90,"PHASE4":92,"NA":94},{"trials":77,"activeCount":54},[],{"trials":79,"activeCount":20,"soonestReadout":40},[80],{"nctId":38,"briefTitle":39,"status":81,"phases":82,"primaryCompletion":40,"completion":83,"start":84,"enrollment":85,"conditions":86,"interventions":87},"NOT_YET_RECRUITING",[44],"2028-06-01","2025-08-01",8,[17],[41],{"trials":89,"activeCount":54},[],{"trials":91,"activeCount":54},[],{"trials":93,"activeCount":54},[],{"trials":95,"activeCount":54},[],{"intervention":97,"totalTrials":20,"cells":98},"Artemeter plus lumefantrina vs artesunato plus amodiquina",{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":120},{"trials":100,"activeCount":54},[],{"trials":102,"activeCount":54},[],{"trials":104,"activeCount":54},[],{"trials":106,"activeCount":54},[],{"trials":108,"activeCount":54},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":119},"NCT04877626","Assessment of the Therapeutic Efficacy and Tolerability of the Artesunate\u002FAmodiaquina Combination and Artemether\u002FLumefantrine Combination, Treatment of Uncomplicated P. Falciparum Malaria in the Department of Chocó (Colombia)","COMPLETED",[47],"2009-10","2009-12","2008-09",210,[19],[97],{"trials":121,"activeCount":54},[],{"intervention":123,"totalTrials":20,"cells":124},"Morphine",{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":144,"NA":146},{"trials":126,"activeCount":54},[],{"trials":128,"activeCount":54},[],{"trials":130,"activeCount":54},[],{"trials":132,"activeCount":54},[133],{"nctId":134,"briefTitle":135,"status":112,"phases":136,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":142},"NCT04887649","Randomized, Controlled, Double Blind, to Evaluate the Postpartum Analgesia With Epidural Morphine: Analgesic Effect of Two Different Doses Compared to Placebo",[46],"2010-04","2011-04","2009-03",114,[24],[123,143,123],"saline solution",{"trials":145,"activeCount":54},[],{"trials":147,"activeCount":54},[],{"intervention":143,"totalTrials":20,"cells":149},{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":156,"PHASE4":162,"NA":164},{"trials":151,"activeCount":54},[],{"trials":153,"activeCount":54},[],{"trials":155,"activeCount":54},[],{"trials":157,"activeCount":54},[158],{"nctId":134,"briefTitle":135,"status":112,"phases":159,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":160,"interventions":161},[46],[24],[123,143,123],{"trials":163,"activeCount":54},[],{"trials":165,"activeCount":54},[],{"intervention":167,"totalTrials":20,"cells":168},"Hydroxychloroquine",{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":187,"NA":189},{"trials":170,"activeCount":54},[],{"trials":172,"activeCount":54},[],{"trials":174,"activeCount":54},[],{"trials":176,"activeCount":54},[177],{"nctId":178,"briefTitle":179,"status":180,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":54,"conditions":185,"interventions":186},"NCT04346329","Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19","WITHDRAWN",[46],"2020-06-30","2020-10-30","2020-03-30",[15],[167],{"trials":188,"activeCount":54},[],{"trials":190,"activeCount":54},[],{"intervention":192,"totalTrials":20,"cells":193},"Fluconazole and Secnidazole",{"EARLY_PHASE1":194,"PHASE1":196,"PHASE2":198,"PHASE3":200,"PHASE4":213,"NA":215},{"trials":195,"activeCount":54},[],{"trials":197,"activeCount":54},[],{"trials":199,"activeCount":54},[],{"trials":201,"activeCount":54},[202],{"nctId":203,"briefTitle":204,"status":112,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":212},"NCT02111629","Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge",[46],"2013-02","2013-05","2012-05",118,[211],"Vaginal Discharge",[192],{"trials":214,"activeCount":54},[],{"trials":216,"activeCount":54},[],{"intervention":218,"totalTrials":20,"cells":219},"Emtricitabine\u002Ftenofovir",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":241,"NA":243},{"trials":221,"activeCount":54},[],{"trials":223,"activeCount":54},[],{"trials":225,"activeCount":54},[],{"trials":227,"activeCount":54},[228],{"nctId":229,"briefTitle":230,"status":112,"phases":231,"primaryCompletion":232,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":238},"NCT04359095","Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia",[45,46],"2021-03-20","2021-06-30","2020-08-18",650,[237],"COVID-19",[218,239,240],"Colchicine Pill","Rosuvastatin",{"trials":242,"activeCount":54},[],{"trials":244,"activeCount":54},[],{"intervention":239,"totalTrials":20,"cells":246},{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":259,"NA":261},{"trials":248,"activeCount":54},[],{"trials":250,"activeCount":54},[],{"trials":252,"activeCount":54},[],{"trials":254,"activeCount":54},[255],{"nctId":229,"briefTitle":230,"status":112,"phases":256,"primaryCompletion":232,"completion":233,"start":234,"enrollment":235,"conditions":257,"interventions":258},[45,46],[237],[218,239,240],{"trials":260,"activeCount":54},[],{"trials":262,"activeCount":54},[],{"intervention":240,"totalTrials":20,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":277,"NA":279},{"trials":266,"activeCount":54},[],{"trials":268,"activeCount":54},[],{"trials":270,"activeCount":54},[],{"trials":272,"activeCount":54},[273],{"nctId":229,"briefTitle":230,"status":112,"phases":274,"primaryCompletion":232,"completion":233,"start":234,"enrollment":235,"conditions":275,"interventions":276},[45,46],[237],[218,239,240],{"trials":278,"activeCount":54},[],{"trials":280,"activeCount":54},[],{"intervention":282,"totalTrials":20,"cells":283},"Ivermectin 0.1% Metronidazole 1%",{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":290,"PHASE4":302,"NA":304},{"trials":285,"activeCount":54},[],{"trials":287,"activeCount":54},[],{"trials":289,"activeCount":54},[],{"trials":291,"activeCount":54},[292],{"nctId":293,"briefTitle":294,"status":112,"phases":295,"primaryCompletion":296,"completion":296,"start":297,"enrollment":298,"conditions":299,"interventions":301},"NCT02236403","Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1%",[46],"2015-01","2014-10",60,[300],"Chronic Blepharitis",[282],{"trials":303,"activeCount":54},[],{"trials":305,"activeCount":54},[],{"intervention":307,"totalTrials":20,"cells":308},"PRP",{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":330,"NA":332},{"trials":310,"activeCount":54},[],{"trials":312,"activeCount":54},[],{"trials":314,"activeCount":54},[],{"trials":316,"activeCount":54},[317],{"nctId":318,"briefTitle":319,"status":112,"phases":320,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":328},"NCT02257957","Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye",[46],"2015-09-30","2016-04-20","2014-11-30",30,[326,327],"Dry Eye","Sjogren Syndrome",[307,329],"Standard care Hyaluronic acid eye drops",{"trials":331,"activeCount":54},[],{"trials":333,"activeCount":54},[],{"intervention":329,"totalTrials":20,"cells":335},{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":340,"PHASE3":342,"PHASE4":348,"NA":350},{"trials":337,"activeCount":54},[],{"trials":339,"activeCount":54},[],{"trials":341,"activeCount":54},[],{"trials":343,"activeCount":54},[344],{"nctId":318,"briefTitle":319,"status":112,"phases":345,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":346,"interventions":347},[46],[326,327],[307,329],{"trials":349,"activeCount":54},[],{"trials":351,"activeCount":54},[],{"intervention":353,"totalTrials":20,"cells":354},"Allogeneic NK transfer",{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":367,"PHASE4":369,"NA":371},{"trials":356,"activeCount":54},[],{"trials":358,"activeCount":54},[],{"trials":360,"activeCount":54},[361],{"nctId":362,"briefTitle":363,"status":180,"phases":364,"primaryCompletion":182,"completion":183,"start":184,"enrollment":54,"conditions":365,"interventions":366},"NCT04344548","Adoptive Cell Transfer for the Immunotherapy of COVID-19 in Colombia",[44,45],[15],[353],{"trials":368,"activeCount":54},[],{"trials":370,"activeCount":54},[],{"trials":372,"activeCount":54},[],{"intervention":374,"totalTrials":20,"cells":375},"Peptide pulsed Dendritic cell",{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":390,"PHASE3":392,"PHASE4":394,"NA":396},{"trials":377,"activeCount":54},[],{"trials":379,"activeCount":54},[380],{"nctId":381,"briefTitle":382,"status":112,"phases":383,"primaryCompletion":384,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":389},"NCT04879888","Personalized Vaccine for Cancer Immunotherapy",[44],"2016-12-30","2017-07-30","2016-08",9,[17],[374],{"trials":391,"activeCount":54},[],{"trials":393,"activeCount":54},[],{"trials":395,"activeCount":54},[],{"trials":397,"activeCount":54},[],{"intervention":399,"totalTrials":20,"cells":400},"Neo-antigen pulsed Dendritic cell",{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":415,"PHASE3":417,"PHASE4":419,"NA":421},{"trials":402,"activeCount":54},[],{"trials":404,"activeCount":54},[405],{"nctId":406,"briefTitle":407,"status":112,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":414},"NCT04105582","Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells",[44],"2020-12-01","2022-02-01","2019-08-01",5,[28,30],[399],{"trials":416,"activeCount":54},[],{"trials":418,"activeCount":54},[],{"trials":420,"activeCount":54},[],{"trials":422,"activeCount":54},[],{"intervention":424,"totalTrials":20,"cells":425},"COVID-19 vaccines",{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":427,"activeCount":54},[],{"trials":429,"activeCount":54},[],{"trials":431,"activeCount":54},[],{"trials":433,"activeCount":54},[],{"trials":435,"activeCount":54},[],{"trials":437,"activeCount":54},[438],{"nctId":439,"briefTitle":440,"status":112,"phases":441,"primaryCompletion":442,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":449},"NCT04887246","Monitoring the Effectiveness and Safety of COVID-19 Vaccines at National University of Colombia",[],"2022-04-15","2022-12-15","2021-03-15",4078,[447,448],"Covid19","SARS-CoV2 Infection",[424],{"intervention":451,"totalTrials":20,"cells":452},"HPV vaccine",{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":457,"PHASE3":459,"PHASE4":461,"NA":463},{"trials":454,"activeCount":54},[],{"trials":456,"activeCount":54},[],{"trials":458,"activeCount":54},[],{"trials":460,"activeCount":54},[],{"trials":462,"activeCount":54},[],{"trials":464,"activeCount":54},[465],{"nctId":466,"briefTitle":467,"status":112,"phases":468,"primaryCompletion":469,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":478},"NCT06700941","Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment",[],"2019-12-31","2020-12-31","2012-01-01",8000000,[474,475,476,477],"Cervical Intraepithelial Neoplasia (CIN)","Genital Warts","Papillomavirus Infections","Cervical Cancers",[451]]